MCID: SZR006
MIFTS: 59

Seizure Disorder

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Seizure Disorder

MalaCards integrated aliases for Seizure Disorder:

Name: Seizure Disorder 54 6 3
Seizures 29 6 43
Epilepsy 72
Seizure 29

Classifications:



External Ids:

UMLS 72 C0014544

Summaries for Seizure Disorder

NINDS : 54 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Seizure Disorder, also known as seizures, is related to seizures, benign familial infantile, 3 and benign neonatal seizures, and has symptoms including seizures, tremor and back pain. An important gene associated with Seizure Disorder is DIAPH1 (Diaphanous Related Formin 1), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Ethosuximide and Nitrazepam have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and cortex, and related phenotype is nervous system.

MedlinePlus : 43 Seizures are symptoms of a brain problem. They happen because of sudden, abnormal electrical activity in the brain. When people think of seizures, they often think of convulsions in which a person's body shakes rapidly and uncontrollably. Not all seizures cause convulsions. There are many types of seizures and some have mild symptoms. Seizures fall into two main groups. Focal seizures, also called partial seizures, happen in just one part of the brain. Generalized seizures are a result of abnormal activity on both sides of the brain. Most seizures last from 30 seconds to 2 minutes and do not cause lasting harm. However, it is a medical emergency if seizures last longer than 5 minutes or if a person has many seizures and does not wake up between them. Seizures can have many causes, including medicines, high fevers, head injuries and certain diseases. People who have recurring seizures due to a brain disorder have epilepsy. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Epilepsy is a broad term used for a brain disorder that causes seizures. There are many different types of epilepsy. There are also many different kinds of seizures.

Wikipedia : 75 Epilepsy is a group of neurological disorders characterized by recurrent epileptic seizures. Epileptic... more...

Related Diseases for Seizure Disorder

Diseases in the Seizure Disorder family:

Seizures, Benign Familial Infantile, 1 Seizures, Benign Familial Infantile, 2
Seizures, Benign Familial Infantile, 3 Seizures, Benign Familial Infantile, 4
Seizures, Benign Familial Infantile, 5

Diseases related to Seizure Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2922)
# Related Disease Score Top Affiliating Genes
1 seizures, benign familial infantile, 3 34.4 SCN2A SCN1A KCNQ2
2 benign neonatal seizures 34.2 SCN2A KCNQ2
3 malignant migrating partial seizures of infancy 33.9 TBC1D24 SCN2A SCN1A
4 benign familial infantile epilepsy 33.3 SCN2A PNPO KCNQ2
5 benign familial neonatal epilepsy 33.0 TBC1D24 SCN2A KCNQ2
6 epilepsy, idiopathic generalized 10 32.9 TBC1D24 SCN2A SCN1A ICK
7 epilepsy, nocturnal frontal lobe, 1 32.2 SCN1A KCNQ2
8 early myoclonic encephalopathy 32.0 TBC1D24 SCN1A CDKL5
9 epilepsy, familial temporal lobe, 3 31.6 SCN2A NLGN1
10 epileptic encephalopathy, early infantile, 9 31.6 SCN1A MECP2 CDKL5
11 epileptic encephalopathy, early infantile, 1 31.1 TBC1D24 KCNQ2
12 epileptic encephalopathy, early infantile, 6 30.8 TBC1D24 SCN2A SCN1A PNPO KCNQ2 CDKL5
13 visual epilepsy 30.4 SCN2A SCN1A PNPO MECP2 KCNQ2 CDKL5
14 encephalopathy 30.3 SCN1A PNPO MECP2 CDKL5
15 focal epilepsy 29.8 TBC1D24 SCN2A SCN1A CDKL5
16 alacrima, achalasia, and mental retardation syndrome 29.7 TBC1D24 SCN1A MECP2
17 epilepsy with generalized tonic-clonic seizures 29.5 TBC1D24 SCN2A SCN1A
18 generalized epilepsy with febrile seizures plus 29.5 TBC1D24 SCN2A SCN1A KCNQ2
19 benign epilepsy with centrotemporal spikes 29.4 TBC1D24 SCN2A KCNQ2 CELF4
20 pervasive developmental disorder 29.2 NLGN1 MECP2 CDKL5
21 epilepsy, idiopathic generalized 29.2 TBC1D24 SCN2A SCN1A KCNQ2
22 west syndrome 29.2 TBC1D24 SCN2A SCN1A MECP2 KCNQ2 CDKL5
23 early infantile epileptic encephalopathy 28.9 TBC1D24 SCN2A SCN1A KCNQ2 CDKL5
24 epilepsy 28.8 TBC1D24 SCN2A SCN1A PNPO MECP2 KCNQ2
25 autism 28.8 SEZ6L2 SCN2A NLGN1 MECP2 CDKL5
26 multiple congenital anomalies-hypotonia-seizures syndrome 2 12.5
27 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 12.5
28 generalized epilepsy with febrile seizures plus, type 9 12.5
29 multiple congenital anomalies-hypotonia-seizures syndrome 1 12.5
30 multiple congenital anomalies-hypotonia-seizures syndrome 3 12.5
31 microcephaly, seizures, and developmental delay 12.4
32 microcephaly, short stature, and polymicrogyria with or without seizures 12.4
33 febrile seizures, familial, 4 12.4
34 seizures, benign familial infantile, 2 12.4
35 seizures, benign familial neonatal, 1 12.4
36 seizures, scoliosis, and macrocephaly/microcephaly syndrome 12.4
37 microcephaly, progressive, with seizures and cerebral and cerebellar atrophy 12.4
38 multiple congenital anomalies-hypotonia-seizures syndrome 12.4
39 rigidity and multifocal seizure syndrome, lethal neonatal 12.4
40 dissociative seizures 12.4
41 febrile seizures, familial, 1 12.4
42 seizures, cortical blindness, and microcephaly syndrome 12.4
43 primary aldosteronism, seizures, and neurologic abnormalities 12.4
44 scn1a-related seizure disorders 12.4
45 hypomagnesemia, seizures, and mental retardation 2 12.4
46 hypomagnesemia, seizures, and mental retardation 1 12.4
47 seizures, benign familial infantile, 5 12.4
48 intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies 12.4
49 neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy 12.4
50 generalized epilepsy with febrile seizures plus, type 4 12.3

Comorbidity relations with Seizure Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Seizure Disorder:



Diseases related to Seizure Disorder

Symptoms & Phenotypes for Seizure Disorder

UMLS symptoms related to Seizure Disorder:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, non-epileptic convulsion

MGI Mouse Phenotypes related to Seizure Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 CDKL5 CELF4 DIAPH1 ICK KCNQ2 MECP2

Drugs & Therapeutics for Seizure Disorder

Drugs for Seizure Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 824)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethosuximide Approved Phase 4 77-67-8 3291
2
Nitrazepam Approved Phase 4 146-22-5 4506
3
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
4
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
5
Lumefantrine Approved Phase 4 82186-77-4 6437380
6
Artemether Approved Phase 4 71963-77-4 68911 119380
7
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
8
Verapamil Approved Phase 4 52-53-9 2520
9
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
10
Acetaminophen Approved Phase 4 103-90-2 1983
11
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Morphine Approved, Investigational Phase 4 57-27-2 5288826
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Methohexital Approved Phase 4 151-83-7 9034
16
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
17
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19
Nicotine Approved Phase 4 54-11-5 942 89594
20
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
21
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
22
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
23
Labetalol Approved Phase 4 36894-69-6 3869
24
Ziprasidone Approved Phase 4 146939-27-7 60854
25
Cosyntropin Approved Phase 4 16960-16-0 16129617
26
Sodium citrate Approved, Investigational Phase 4 68-04-2
27
Levodopa Approved Phase 4 59-92-7 6047
28
Cycloserine Approved Phase 4 68-41-7 6234 401
29
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
30
Imipramine Approved Phase 4 50-49-7 3696
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
32
Norepinephrine Approved Phase 4 51-41-2 439260
33
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
34
Nortriptyline Approved Phase 4 72-69-5 4543
35
Clevidipine Approved, Investigational Phase 4 167221-71-8
36
Hydralazine Approved Phase 4 86-54-4 3637
37
Clonidine Approved Phase 4 4205-90-7 2803
38
Ticagrelor Approved Phase 4 274693-27-5 9871419
39
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
40
Liraglutide Approved Phase 4 204656-20-2 44147092
41
Pasireotide Approved Phase 4 396091-73-9 9941444
42
Parecoxib Approved Phase 4 198470-84-7
43
Dobutamine Approved Phase 4 34368-04-2 36811
44
Codeine Approved, Illicit Phase 4 76-57-3 5284371
45
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
46
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
47
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
48
Ephedrine Approved Phase 4 299-42-3 9294
49
Pseudoephedrine Approved Phase 4 90-82-4 7028
50
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554

Interventional clinical trials:

(show top 50) (show all 2759)
# Name Status NCT ID Phase Drugs
1 Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study Unknown status NCT02726919 Phase 4 Clobazam
2 A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years Unknown status NCT02205931 Phase 4 Antiepileptic drug therapy
3 Study to Improve the Treatment of Epilepsy (SITE). A Randomized Study Comparing Adjustment of Treatment to Reduce Side Effects of Antiepileptic Drugs With Continuing Treatment Unchanged Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
4 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
5 Efficacy of Levetiracetam in Control of Neonatal Seizures Unknown status NCT03107507 Phase 4 Levetiracetam;Phenobarbital
6 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
7 Comparing Ketogenic Diet With the Most Appropriate Antiepileptic Drug- a Randomized Study of Children With Mental Retardation and Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
8 A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
9 Double Blind, Randomised, Cross-over Study Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
10 Hormone Profiles in Adults Treated With Valproate vs. Lamotrigine Monotherapy for Newly Diagnosed Epilepsy: A Prospective Randomised Study Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
11 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) - a Placebo Controlled Double-blind Cross-over-study Unknown status NCT00393614 Phase 4 levetiracetam
12 Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy: Efficacy, Tolerability, Dosing Equivalence, and Retention Rate Unknown status NCT01932502 Phase 4 clobazam (Onfi);Initial conversion and titration;Conversion schedule - Week 1;Conversion schedule - Week 2;Conversion schedule - Week 3
13 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
14 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
15 Melatonin Use in the Intensive Care Elderly Population Unknown status NCT03013790 Phase 4 Melatonin
16 Combining Propofol With Therapeutic Hypothermia for Improving Survival and Neurological Prognoses in Patients Resuscitated From Cardiac Arrest Unknown status NCT02367755 Phase 4 Propofol;Lorazepam
17 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
18 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
19 Inonu University, Turgut Ozal Medical Center, Department of Anesthesiology and Reanimation Malatya Unknown status NCT02271555 Phase 4 Sevoflurane;Remifentanil;Saline
20 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
21 Conversion From Multiple-Daily Dose Enteric-Coated Depakote to Once-Daily Depakote ER in Elderly Outpatients With Epilepsy or Behavioral Disturbances: Unknown status NCT00312676 Phase 4
22 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging Unknown status NCT00132223 Phase 4 Contrast agent
23 Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children: A Prospective Randomized Control Study Unknown status NCT02408302 Phase 4 Midazolam
24 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
25 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
26 A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty Unknown status NCT02497911 Phase 4 Ropivicaine;Bupivicaine
27 The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism Unknown status NCT01479075 Phase 4 intransal insulin;Placebo
28 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
29 A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty Unknown status NCT02603900 Phase 4 ropivacaine;bupivacaine
30 Effect of Bispectral Index (BIS) Monitoring on Faster Recovery Time and Analgesic Consumption in Abdominal Surgery Patients Unknown status NCT01470898 Phase 4
31 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
32 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Unknown status NCT02851303 Phase 4 Morphine;Methadone
33 Pharmacokinetic/Pharmacodynamic Model of Propofol in Children Unknown status NCT02544854 Phase 4 Propofol
34 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
35 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
36 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Unknown status NCT02298660 Phase 4 BOTOX
37 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
38 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
39 A Randomized, Open Label, Comparative, Multi-center Clinical Trial to Determine the Efficacy and Safety of Topiramate Comparing With Carbamazepine in Benign Rolandic Epilepsy. Completed NCT00216567 Phase 4 topamax
40 A 24-Week Prospective, Open-Label, Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Adult Patients With Partial Seizures Completed NCT00275925 Phase 4 Oxcarbazepine
41 A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. Completed NCT00537940 Phase 4 Pregabalin;Gabapentin
42 A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures Completed NCT00275912 Phase 4 Oxcarbazepine
43 A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
44 IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures Completed NCT00510783 Phase 4 Keppra;Fosphenytoin;Dilantin
45 A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures Completed NCT01229735 Phase 4 Levetiracetam;Topiramate
46 Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy Completed NCT00004637 Phase 4 Vitamin E
47 IV Lacosamide: The Safety of Intravenous Lacosamide Completed NCT00832884 Phase 4 Lacosamide;Lacosamide;Lacosamide;Lacosamide;Lacosamide;Lacosamide;Lacosamide;Lacosamide
48 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
49 Lyrica (Pregabalin) Administered As An Add-On Therapy For Partial Seizures (LEADER) An Open-Label, Multicenter Add-On Therapy Trial Completed NCT00288639 Phase 4 Pregabalin
50 Phase IV Study of Cognitive and Behavioral Effects of Lacosamide as Adjunctive Therapy in Patients With Partial Epilepsy Completed NCT01175954 Phase 4 Lacosamide;Lacosamide

Search NIH Clinical Center for Seizure Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Anti-epileptic Agent [EPC]
Divalproex Sodium
Ethosuximide
Ethotoin
felbamate
fosphenytoin
Fosphenytoin sodium
gabapentin
gabapentin enacarbil
lacosamide
lamotrigine
Levetiracetam
Mephenytoin
methsuximide
oxcarbazepine
Phenytoin
Phenytoin sodium
PHENYTOIN SODIUM,EXTENDED
PHENYTOIN SODIUM,PROMPT
Primidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
Trimethadione
Valproic Acid
Vigabatrin
zonisamide

Genetic Tests for Seizure Disorder

Genetic tests related to Seizure Disorder:

# Genetic test Affiliating Genes
1 Seizures 29
2 Seizure 29

Anatomical Context for Seizure Disorder

MalaCards organs/tissues related to Seizure Disorder:

41
Brain, Temporal Lobe, Cortex, Amygdala, Testes, Heart, Bone

Publications for Seizure Disorder

Articles related to Seizure Disorder:

(show top 50) (show all 31664)
# Title Authors PMID Year
1
ECS Dynamism and Its Influence on Neuronal Excitability and Seizures. 38 17
30879174 2019
2
Patient-Friendly Summary of the ACR Appropriateness Criteria: Seizures-Child. 38 17
30717835 2019
3
Testicular mixed germ cell tumor presenting with seizure as the initial symptom: a case report and literature review. 17
30912892 2019
4
Traumatic lingual haematoma: Another unusual cause of upper airway obstruction in systemic lupus erythematosus. 38
31372486 2019
5
Ionic and synaptic mechanisms of seizure generation and epileptogenesis. 38
31150792 2019
6
Inhibition, oscillations and focal seizures: An overview inspired by some historical notes. 38
31125597 2019
7
Congenital Cranial Dysinnervation Disorder: An Unusual Phenotype With Multiple Cranial Neuropathies and Novel Neuroimaging Findings. 38
31008839 2019
8
The role of the surgical technique in incidence of postoperative epileptic seizures in unruptured intracranial aneurysm clipping. 38
31279607 2019
9
Significance of automated external defibrillator in identifying lethal ventricular arrhythmias. 38
31297625 2019
10
A missense variant of SMC1A causes periodic pharmaco-resistant cluster seizures similar to PCDH19-related epilepsy. 38
31185419 2019
11
Cerebral aquaporin-4 expression is independent of seizures in tuberous sclerosis complex. 38
31078684 2019
12
Supratentorial Neurenteric Cyst: A Rare Differential for a Frontal Cyst. 38
31426248 2019
13
Neurovascular Lesions in Pediatric Epilepsy. 38
31066328 2019
14
Clinical implications of scalp ictal EEG pattern in patients with temporal lobe epilepsy. 38
31319289 2019
15
From adagio to allegretto: The changing tempo of theta frequencies in epilepsy and its relation to interneuron function. 38
30798003 2019
16
Simultaneous bilateral neck of femur fractures in an adolescent secondary to hypocalcaemic seizure. 38
30308552 2019
17
First seizure presentations in adults: beyond assessment and treatment. 38
30948624 2019
18
Continuous EEG monitoring after brain tumor surgery. 38
31278599 2019
19
Characterisation of neonatal seizures and their treatment using continuous EEG monitoring: a multicentre experience. 38
30472660 2019
20
Seizures in glioma patients: An overview of incidence, etiology, and therapies. 38
31352293 2019
21
The mGlu7 receptor provides protective effects against epileptogenesis and epileptic seizures. 38
31051234 2019
22
Correlation between glioma location and preoperative seizures: a systematic review and meta-analysis. 38
30073426 2019
23
Focal epileptic seizures anticipation based on patterns of heart rate variability parameters. 38
31416541 2019
24
Comparison of kainate-induced seizures, cognitive impairment and hippocampal damage in male and female mice. 38
31269415 2019
25
The effect of exercise on GABA signaling pathway in the model of chemically induced seizures. 38
31326567 2019
26
Hyperkinetic movement disorders in congenital disorders of glycosylation. 38
31132195 2019
27
Potassium Bromide in the Treatment of Pediatric Refractory Epilepsy. 38
31111774 2019
28
Predominantly nocturnal seizures post temporal lobectomy: Characteristics of an unusual outcome group. 38
31254798 2019
29
Focal cortical dysplasia II-related seizures originate from the bottom of the dysplastic sulcus: A stereoelectroencephalography study. 38
31319288 2019
30
Neurodevelopmental outcomes at 9-14 months gestational age after treatment of neonatal seizures due to brain injury. 38
31278442 2019
31
"Mini" occipital seizures with accompanying ultra-slow waves (DC shift) on SEEG in a 14-year old child. 38
31227404 2019
32
Dexmedetomidine to Treat 3, 4-Methylenedioxymethamphetamine-Induced Agitation in a 13-Month-Old Infant: A Case Report and Literature Review. 38
31404223 2019
33
Natural product incarvillateine aggravates epileptic seizures by inhibiting GABAA currents. 38
31242440 2019
34
Parallel pathways of seizure generalization. 38
31237945 2019
35
Leaking the Diagnosis: A Case of Convulsive Status Epilepticus Due to Intracranial Hypotension. 38
31372926 2019
36
A young woman with seizures, visual impairment, and paralysis. 38
31429234 2019
37
Chronic alcohol abuse affects the clinical course and outcome of community-acquired bacterial meningitis. 38
31392446 2019
38
Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. 38
31382178 2019
39
Gene mutations in paediatric epilepsies cause NMDA-pathy, and phasic and tonic GABA-pathy. 38
30680721 2019
40
Electrographic seizure burden and outcomes following pediatric status epilepticus. 38
31420288 2019
41
Periodic focal epileptiform discharges. 38
31185363 2019
42
Outcome of Nonketotic Hyperglycinemia in Lebanon: 14-Year Retrospective Review. 38
31170734 2019
43
Extent of Resection and Residual Tumor Thresholds for Postoperative Total Seizure Freedom in Epileptic Adult Patients Harboring a Supratentorial Diffuse Low-Grade Glioma. 38
30395304 2019
44
Suppressive effects of levetiracetam on neuroinflammation and phagocytic microglia: A comparative study of levetiracetam, valproate and carbamazepine. 38
31276728 2019
45
Efficacy of phenobarbital for benign convulsions with mild gastroenteritis: A randomized, placebo-controlled trial. 38
30954360 2019
46
Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. 38
31263255 2019
47
A de novo variant in the X-linked gene CNKSR2 is associated with seizures and mild intellectual disability in a female patient. 38
31414730 2019
48
A potential role of hypophosphatemia for diagnosing convulsive seizures: A case-control study. 38
31211423 2019
49
Treatment of drug-resistant epilepsy in patients with periventricular nodular heterotopia using RNS® System: Efficacy and description of chronic electrophysiological recordings. 38
31163364 2019
50
An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome. 38
31373526 2019

Variations for Seizure Disorder

ClinVar genetic disease variations for Seizure Disorder:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 DIAPH1 NM_005219.5(DIAPH1): c.2332C> T (p.Gln778Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730882242 5:140953085-140953085 5:141573518-141573518
2 MTR NM_000254.2(MTR): c.3518C> T (p.Pro1173Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913578 1:237058770-237058770 1:236895470-236895470
3 SCN1A NM_006920.6(SCN1A): c.1625G> A (p.Arg542Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs121918817 2:166901590-166901590 2:166045080-166045080

Expression for Seizure Disorder

Search GEO for disease gene expression data for Seizure Disorder.

Pathways for Seizure Disorder

Pathways related to Seizure Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 SCN2A SCN1A MECP2 KCNQ2
2
Show member pathways
11.43 SCN2A SCN1A KCNQ2
3 10.28 SCN2A SCN1A KCNQ2

GO Terms for Seizure Disorder

Cellular components related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon initial segment GO:0043194 9.26 SCN1A KCNQ2
2 voltage-gated sodium channel complex GO:0001518 9.16 SCN2A SCN1A
3 sodium channel complex GO:0034706 8.96 SCN2A SCN1A
4 node of Ranvier GO:0033268 8.8 SCN2A SCN1A KCNQ2

Biological processes related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of ion transmembrane transport GO:0034765 9.54 SCN2A SCN1A KCNQ2
2 neuron projection development GO:0031175 9.5 TBC1D24 NLGN1 MECP2
3 neuronal action potential GO:0019228 9.4 SCN2A SCN1A
4 positive regulation of dendritic spine development GO:0060999 9.26 NLGN1 CDKL5
5 membrane depolarization during action potential GO:0086010 9.16 SCN2A SCN1A
6 regulation of respiratory gaseous exchange by neurological system process GO:0002087 8.96 NLGN1 MECP2
7 neuromuscular process controlling posture GO:0050884 8.62 SCN1A MECP2

Molecular functions related to Seizure Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium channel activity GO:0005272 9.16 SCN2A SCN1A
2 voltage-gated ion channel activity GO:0005244 9.13 SCN2A SCN1A KCNQ2
3 voltage-gated sodium channel activity GO:0005248 8.62 SCN2A SCN1A

Sources for Seizure Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....